<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845920</url>
  </required_header>
  <id_info>
    <org_study_id>SheffieldHallamAquili2019</org_study_id>
    <nct_id>NCT03845920</nct_id>
  </id_info>
  <brief_title>Mod of Cognitive Flexibility by tDCS, Tyrosine Polymorphisms in the COMT Gene</brief_title>
  <official_title>Modulation of Cognitive Flexibility by Transcranial Direct Current Stimulation, Tyrosine Administration and Polymorphisms in the COMT Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Hallam University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Hallam University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study would examine whether increases in endogenous dopaminergic activity via
      tyrosine and the (presumed) excitation of these by anodal tDCS of the dlPFC could causally be
      related to cognitive flexibility as measured by task switching and reversal learning.

      Additionally, the study will test whether the Val158Met-polymorphism in the catechol-
      O-methyltransferase (COMT) gene could also predict the effect of TYR supplementation, as this
      gene is involved in DA degradation in the prefrontal cortex.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wisconsin Card Sorting Test (WCST) performance</measure>
    <time_frame>Measured twice in each session (4 arms): at time 0 and 80 minutes into testing.</time_frame>
    <description>Measuring change in perseverative errors in the WCST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Probabilistic Reversal Learning (PRL) performance</measure>
    <time_frame>Measured twice in each session (4 arms): at time 0 and 80 minutes into testing.</time_frame>
    <description>Measuring change in reversal errors in the WCST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flanker Task performance</measure>
    <time_frame>Measured twice in each session (4 arms): at time 0 and 80 minutes into testing.</time_frame>
    <description>Measuring change in conflict cost (defined as the difference in reaction time between congruent and incongruent responses)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Modulation of Cognitive Flexibility by Transcranial Direct Current Stimulation, Tyrosine Administration and Polymorphisms in the COMT Gene</condition>
  <arm_group>
    <arm_group_label>tDCS sham + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS sham + tyrosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS anodal + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS anodal +tyrosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>tdcs (sham/anodal) + drug (placebo/tyrosine)</intervention_name>
    <description>tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.
Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols.</description>
    <arm_group_label>tDCS anodal + placebo</arm_group_label>
    <arm_group_label>tDCS anodal +tyrosine</arm_group_label>
    <arm_group_label>tDCS sham + placebo</arm_group_label>
    <arm_group_label>tDCS sham + tyrosine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Either male or female

               -  Between 18 and 30 years

               -  You are in good health

               -  You agree to fast overnight prior to testing

        Exclusion Criteria:

          -  • Are suffering from cardiac, hepatic, renal, neurological disorders

               -  Damaged or diseased skin on your face and scalp, or a sensitive scalp

               -  A history of alcohol or drug addiction, or severe psychiatric illness

               -  Drug treatment which may lower seizure threshold (i.e. epilepsy)

               -  Pregnancy

               -  Sleep deprivation (less than 6 hours a day)

               -  A history of migraine or headaches

               -  A history of taking antidepressants

               -  A history of taking tyrosine supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Aquili, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Hallam University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Aquili, Ph.D.</last_name>
    <phone>+ 44 (0) 114 225</phone>
    <phone_ext>6991</phone_ext>
    <email>luca.aquili@shu.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Macaskill, Ph.D.</last_name>
    <phone>44 (0)114 225</phone>
    <phone_ext>4604</phone_ext>
    <email>a.macaskill@shu.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychology labs</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Wallace, BSc</last_name>
      <phone>0114 225</phone>
      <phone_ext>5953</phone_ext>
      <email>l.j.wallace@shu.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Crawford, MSc</last_name>
      <phone>0114 225</phone>
      <phone_ext>3554</phone_ext>
      <email>j.d.crawford@shu.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

